Departure and appointment · 9 October 2026
IRulya Therapeutics Inc.
QNCX · Listed
Key facts
- How the CEO left
- Resignation
- Planned or abrupt
- Planned
- Successor
- Internal (a current executive)
- Outgoing CEO stays as
- Leaves the company
- Signs it was forced
- None stated
- Other news alongside
- None
- Effective
- 8 October 2026
Read from the filing and press release by a language model (Google Gemini), told to use only that text. It can make mistakes; the quotes below are the source.
The announcement
Resignation of Officers As previously announced, effective as of October 8, 2026, Dirk Thye, M.D., resigned as Chief Executive Officer and Chief Medical Officer, as well as a director, of Quince Therapeutics, Inc., which will be renamed IRulya Therapeutics Inc. effective at 4:01 p.m., Eastern Time, on October 9, 2026 (the “ Company ”), and Brendan Hannah resigned as Chief Operating Officer, Chief Business Officer and Chief Compliance Officer of the Company.
Appointment of Chief Executive Officer Effective October 8, 2026 (the “ Effective Date ”), the Board of Directors (the “ Board ”) of the Company appointed Brigette Roberts, M.D., as Chief Executive Officer of the Company.
In connection with Dr. Roberts’ appointment as Chief Executive Officer, the Board determined that Dr. Roberts will succeed Mr. Thye as the Company’s principal executive officer, effective as of the Effective Date.
Sentences matched by our CEO change rules, from the first filing. Read the 8-K on SEC EDGAR ↗
Share price reaction
The filing reached SEC EDGAR on 9 October 2026 at 07:59 New York time, before the market opened, so day 0 is that same day. Day 0 is marked by the vertical line.
| Window | QNCX | S&P 500 | Abnormal |
|---|---|---|---|
| Days 0 to +1 | +10.4% | +0.5% | +7.9% |
| Days 0 to +3 | +2.2% | −0.6% | +2.8% |
| 1 month (days 0 to +21)so far, 13 of 22 days | +10.6% | −0.6% | +9.3% |
| 3 months (days 0 to +63)so far, 13 of 64 days | +10.6% | −0.6% | +9.3% |
The abnormal return is the stock's return beyond what its usual relationship with the market (beta 2.10) predicts. A single stock's move can reflect other news on the same days, so it describes what happened rather than measuring the effect of the CEO change; averages across many events are on the Research design page as they are completed.
News coverage
No matching headlines found. Coverage is thinner for smaller companies.